article thumbnail

Investigating antipsychotics in a Parkinson’s disease psychosis model

Drug Target Review

Clozapine induced a significantly different brain state and pimavanserin, the only licensed compound for PD-P, turned out to be more similar to Mesdopetam on the global scale. During the years 2007-2010 he served as board member of SwedenBIO, the Swedish Biotech industry association. In 2013, Nicholas co-founded IRLAB Sweden.

Disease 105
article thumbnail

FDA More Selective About Convening Advisory Committee Panels During Pandemic | 2021-01-18

The Pharma Data

FDA advisory committees recommended just 50 percent of the 18 new therapies and indications they reviewed in 2020, the lowest rate since 2007, and the agency seems to be reserving the panels for more problematic applications, according to Prevision Policy, a Washington, D.C.-based based research firm.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Part 2: What impact has Brexit had on UK drug discovery?

Drug Discovery World

A significant number of patients have benefited in this clinical trial and through EAMS patients can access this combination in routine clinical practice as quickly as possible.” In terms of Innovate UK, which has been in action since July 2007, the impact in a post-Bexit climate on UK innovation and development has been consistent.

article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

Linda Powers, CEO, Northwest Biotherapeutics Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.

article thumbnail

Cell and gene therapy – where is the innovation? 

Drug Discovery World

The UK also benefits from expedited pathways to development and adoption of novel medicines through the Innovative Licensing and Access Pathway, co-developed by the Medicines and Healthcare Products Regulatory Agency (MHRA), NICE and the Scottish Medicines Consortium (SMC).?- Neelam Patel, CEO of London cluster organisation, MedCity. .

Therapies 130
article thumbnail

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

The Pharma Data

The Janssen dengue compound discovery program started in 2007. licensed the compound series in 2015, and is continuing to advance the compound into clinical development. This effort built upon four years of work on the novel antiviral inhibitor by KU Leuven Rega Institute, CD3, and the Wellcome Trust. Janssen Pharmaceutica, N.V.

Virus 52
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators.

Drugs 189